GleamWall
中文EN

CTOR CITIUS ONCOLOGY, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1851484 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-73.3%
TTM EPS YoY-26.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-126.6%
ROA-45.2%
ROIC (approx.)-132.9%
Asset turnover—

Leverage & solvency

Liabilities / assets64.0%
Debt / equity0.00x
Current ratio0.73x
Interest coverage-128.56x

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue$1.49M$1.67M$3.94M—————
Cost of revenue$491,843$328,878$789,208—————
Gross profit$1.00M$1.34M$3.15M—————
R&D expense$218,496$1.08M$1.02M$1.08M$938,277$3.14M$1.26M$1.30M
SG&A expense$4.22M$23.63M$2.86M$1.34M$1.88M$2.24M$3.32M$3.71M
Operating income-$8.72M-$28.61M-$5.25M-$4.71M-$4.94M-$7.47M-$6.39M-$6.67M
Interest expense$231,732$33,031$45,841$57,277$160,755———
Pretax income-$9.03M-$26.84M-$5.27M-$4.73M-$5.11M-$7.47M-$6.39M-$6.67M
Income tax-$107,347-$231,210$264,240$264,240$264,240$264,240$264,240$144,000
Net income-$8.92M-$26.61M-$5.53M-$5.00M-$5.37M-$7.74M-$6.66M-$6.81M
EPS (basic)-0.08-0.27-0.06—-0.08-0.11-0.09—
EPS (diluted)-0.08-0.27-0.06—-0.08-0.11-0.09—
Weighted avg. shares (diluted)107.89M100.03M87.46M—71.55M71.55M71.55M—
Balance sheet
Cash & equivalents$16.56M$2.63M$7.30M$3.92M$112$112$112$112
Receivables$686,235$1.08M$4.05M—————
Inventory$22.63M$22.66M$22.64M$22.29M$17.21M$15.34M$14.38M$8.27M
Current assets$42.71M$29.42M$37.15M$27.54M$18.31M$18.04M$17.08M$10.97M
Total assets$112.09M$100.70M$109.97M$100.94M$91.71M$91.44M$90.48M$84.37M
Current liabilities$58.79M$58.81M$44.71M$49.49M$52.99M$49.74M$43.40M$32.70M
Total liabilities$71.71M$65.43M$51.56M$56.08M$59.31M$55.80M$49.19M$38.23M
Shareholders' equity$40.38M$35.27M$58.41M$44.87M$32.40M$35.64M$41.29M$46.14M
Shares outstanding105.76M92.98M84.80M83.51M71.55M71.55M71.55M71.55M
Cash flow statement
Operating cash flow-$2.71M-$3.83M-$7.35M————$902,926
Investing cash flow-$2.00M-$600,000-$4.40M————-$29.15M
Financing cash flow$18.64M-$231,199$15.13M————$28.27M
Stock-based compensation$3.56M$3.53M$3.96M$2.30M$2.13M$2.09M$1.81M$1.67M

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.